Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
P/B ratio for Revenio Group Oyj (REG1V.HE)
P/B ratio as of 2023: 7.23
According to Revenio Group Oyj's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.23. At the end of 2022 the company had a P/B ratio of 11.29.
P/B ratio history for Revenio Group Oyj from 2002 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 7.23 |
| 2022 | 11.29 |
| 2021 | 18.81 |
| 2020 | 19.20 |
| 2019 | 10.46 |
| 2018 | 16.84 |
| 2017 | 18.53 |
| 2016 | 15.42 |
| 2015 | 14.61 |
| 2014 | 9.50 |
| 2013 | 6.46 |
| 2012 | 2.09 |
| 2011 | 0.22 |
| 2010 | 1.59 |
| 2009 | 0.17 |
| 2008 | 1.34 |
| 2005 | 3.12 |
| 2004 | 1.84 |
| 2003 | 7.64 |
| 2002 | 1.25 |